🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against superbug strains of the infection, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting more than 82 million new cases each year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs currently available.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

Based on findings published in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The trial included over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have expressed optimism. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.